Illumina, Inc. $ILMN Shares Sold by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 1.2% during the third quarter, Holdings Channel.com reports. The firm owned 459,543 shares of the life sciences company’s stock after selling 5,436 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Illumina were worth $43,643,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. California Public Employees Retirement System raised its stake in shares of Illumina by 6.0% during the 3rd quarter. California Public Employees Retirement System now owns 327,679 shares of the life sciences company’s stock worth $31,120,000 after buying an additional 18,534 shares in the last quarter. Bank of Nova Scotia acquired a new stake in shares of Illumina in the 3rd quarter valued at approximately $373,000. Alliancebernstein L.P. boosted its stake in shares of Illumina by 15.3% in the third quarter. Alliancebernstein L.P. now owns 235,353 shares of the life sciences company’s stock valued at $22,351,000 after buying an additional 31,219 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in Illumina by 48.6% during the third quarter. Ameriprise Financial Inc. now owns 460,706 shares of the life sciences company’s stock worth $43,750,000 after acquiring an additional 150,611 shares during the period. Finally, Creative Planning grew its holdings in Illumina by 25.0% during the third quarter. Creative Planning now owns 55,488 shares of the life sciences company’s stock worth $5,270,000 after acquiring an additional 11,102 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Buying and Selling

In related news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the sale, the senior vice president owned 16,321 shares in the company, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.17% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on ILMN shares. Robert W. Baird set a $137.00 target price on Illumina in a report on Friday, February 6th. Piper Sandler lowered their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. JPMorgan Chase & Co. cut their price target on shares of Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a report on Friday, February 6th. TD Cowen reiterated a “hold” rating on shares of Illumina in a research note on Wednesday, January 7th. Finally, Barclays boosted their price objective on shares of Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Six equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $129.69.

Illumina Price Performance

ILMN stock opened at $118.94 on Monday. The stock’s 50 day moving average price is $133.15 and its 200 day moving average price is $120.10. The firm has a market cap of $18.19 billion, a P/E ratio of 21.82, a PEG ratio of 2.28 and a beta of 1.45. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $155.53.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter last year, the business posted $0.95 earnings per share. Illumina’s revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.